Gracey Craig sold $24K of OMDA

Gracey Craig (Chief Accounting Officer) sold 1,042 shares of Omada Health, Inc. (OMDA) at an average of $22.61 ($22.00–$23.00) across 2 trades over 2026-06-30 to 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Gracey Craig
Published Jul 2, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 7:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Neutral
high confidence
Mentioned
$OMDA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDANeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not provide new operational, financial, or regulatory information about Omada.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the 10b5-1 structure and small dollar amount limit trading impact.

03

What to watch

The filing does not disclose reasons for the sale, and the transaction size is modest, reducing the likelihood of a durable signal.

Relevance 2/10Novelty 3/10Timing: filed July 2, covering sales executed June 30 to July 1

Background

The article is an SEC Form 4 insider transaction disclosure for Omada Health, Inc.

Company-level read

Ticker impact

$OMDANeutralHigh confidence
Context

Omada Health CFO Gracey Craig sold $23,561 of OMDA shares via a 10b5-1 plan on June 30 to July 1 at $22 to $23.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, but it is explicitly tied to a pre-arranged 10b5-1 plan and the disclosed value is relatively small versus typical market-moving thresholds.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None.

None.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Omada Health, Inc.

    Company whose shares were sold by an officer under a 10b5-1 plan.

  • Gracey Craig

    Chief Accounting Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.